To investigate the prevalence and clinical significance of PP2A inhibition, we quantified SET, CIP2A and phosphorylated PP2A (p-PP2A) expression in a cohort of 230 patients with early breast cancer mainly treated with anthracyclin-based adjuvant chemotherapy. The gene discussed is PTPA; the disease is breast carcinoma.